Indication
Vancomycin resistant Enterococcus faecium bacteremia
Vancomycin-resistant *Enterococcus faecium* bacteremia is a serious bloodstream infection caused by strains of the Gram-positive bacterium *Enterococcus faecium* that have acquired resistance to glycopeptide antibiotics, most notably via *vanA* or *vanB* gene clusters that alter cell-wall peptidoglycan precursors. Read more about Vancomycin resistant Enterococcus faecium bacteremia
53 drugs 36 manufacturers
Drugs that treat it
Common Vancomycin resistant Enterococcus faecium bacteremia therapies.
LINEZOLID
LINEZOLID-D5W (linezolid in dextrose 5 % in water)
LINEZOLID-D5W (linezolid in dextrose 5 % in water)
LINEZOLID-D5W (linezolid in dextrose 5 % in water)
LINEZOLID-D5W (linezolid in dextrose 5 % in water)
LINEZOLID
LINEZOLID
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonVancomycin-resistant *Enterococcus faecium* bacteremia is a serious bloodstream infection caused by strains of the Gram-positive bacterium *Enterococcus faecium* that have acquired resistance to glycopeptide antibiotics, most notably via *vanA* or *vanB* gene clusters that alter cell-wall peptidoglycan precursors.
Predominantly a healthcare-associated infection, it typically affects hospitalized, severely ill, or immunocompromised individuals, including patients with indwelling central venous catheters, prolonged broad-spectrum antibiotic exposure, or recent abdominal surgery.
Pathophysiologically, colonized bacteria translocate across compromised mucosal barriers or enter through intravascular devices directly into the systemic circulation, triggering systemic inflammatory manifestations such as fever, tachycardia, hemodynamic instability, and potentially lethal sepsis.
- nih.gov
Vancomycin-resistant *Enterococcus faecium* bacteremia is a serious bloodstream infection caused by strains of the Gram-positive bacterium *Enterococcus faecium* that have acquired resistance to glycopeptide antibiotics, most notably via *vanA* or *vanB* gene clusters that alter cell-wall peptidoglycan precursors
- cdc.gov
Predominantly a healthcare-associated infection, it typically affects hospitalized, severely ill, or immunocompromised individuals, including patients with indwelling central venous catheters, prolonged broad-spectrum antibiotic exposure, or recent abdominal surgery
- nih.gov
Predominantly a healthcare-associated infection, it typically affects hospitalized, severely ill, or immunocompromised individuals, including patients with indwelling central venous catheters, prolonged broad-spectrum antibiotic exposure, or recent abdominal surgery Pathophysiologically, colonized bacteria translocate across compromised mucosal barriers or enter through intravascular devices directly into the systemic circulation, triggering systemic inflammatory manifestations such as fever, ta...
- nih.gov
Predominantly a healthcare-associated infection, it typically affects hospitalized, severely ill, or immunocompromised individuals, including patients with indwelling central venous catheters, prolonged broad-spectrum antibiotic exposure, or recent abdominal surgery Pathophysiologically, colonized bacteria translocate across compromised mucosal barriers or enter through intravascular devices directly into the systemic circulation, triggering systemic inflammatory manifestations such as fever, ta...
Personalize your experience
Follow Vancomycin resistant Enterococcus faecium bacteremia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.